Last but not least: antibody–drug conjugates in hormone receptor-positive metastatic breast cancer
- 7 October 2020
- journal article
- editorial
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (12), 1594-1596
- https://doi.org/10.1016/j.annonc.2020.10.001
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102Journal of Clinical Oncology, 2018
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyJournal of Clinical Oncology, 2017
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trialThe Lancet Oncology, 2017
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Oncology, 2016
- Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studiesBreast Cancer Research and Treatment, 2014
- Effects of Second and Subsequent Lines of Chemotherapy for Metastatic Breast CancerClinical Breast Cancer, 2014
- Trop-2 Is a Determinant of Breast Cancer SurvivalPLOS ONE, 2014
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- Cure of Xenografted Human Carcinomas by BR96-Doxorubicin ImmunoconjugatesScience, 1993